Fresh analysis reveals that people who stop using new GLP-1 drugs like Mounjaro or Wegovy tend to recover reduced body mass much more quickly than those who stop conventional lifestyle programs.
Published data in a prominent medical journal shows that while overweight people often shed a large proportion of their total mass while using the jabs, the mass comes back at an average rate of 0.8 kg per month once they quit.
"Users purchasing such drugs should be aware of the risk of fast weight regain when the medication ends," cautioned expert Dr. Susan Jebb.
That rate of regain means a return to pre-treatment mass within about one and a half years.
Weighing Therapies
The study, which looked at dozens of trials involving over 9,000 of participants, compared the outcomes of these new drugs with older methods.
Scientists emphasize that individuals who shed pounds through lifestyle changes alone typically experience a more gradual creep back—approximately 0.1 kg a month—post-intervention.
The Reason for the Fast Rebound
Nutrition scientists believe the way of the jabs is key to understanding the heightened weight return.
The injections copy a body's own chemical called GLP-1, which helps regulate feelings of fullness.
"Artificially providing GLP-1 concentrations far above than normal may cause the system to produce less of its endogenous hormone, and could diminish responsiveness to its actions," said Dr. Adam Collins, a nutrition specialist.
"Stopping of this medication results in appetite is no longer kept in check, making overeating a significant risk."
A Chronic Condition?
Medical guidelines advise the jabs for individuals with weight-linked medical conditions, accompanied by recommended lifestyle changes.
Professionals argue that, given the significant potential of weight regain, the therapy is often long-term.
This perspective is reinforced by drug manufacturers, who state that the findings "highlight the chronic nature of obesity," comparing it to managing conditions like diabetes.
User Testimonies
People who have discontinued the medication describe a powerful return of appetite.
"I experienced something activating and you become ravenous," recalled an individual.
This difficulty is compounded if users have not developed sustainable lifestyle or habit changes during therapy.
Widespread Use
Survey data indicate that millions of people in the UK have used these injections in the past year, with demand remaining high.
- Use is more common among women compared to men.
- The middle-aged demographic shows the highest level of interest.
- A large proportion access the drugs through private healthcare rather than the NHS.
In conclusion, clinicians stress that while the jabs are potent tools for shedding pounds, they are not a permanent fix and long-term success relies on integrated behavioural changes.
